Gabapentin — research review 2

...and that brings us to gabapentin. Not the drug itself, but the biological target it works on: the alpha-2-delta subunit of voltage-gated calcium channels. It’s where a lot of pain signaling happens.

Right. And for many, these drugs are crucial for managing neuropathic pain. But there’s a broader conversation about pain, aging, and all-cause mortality that’s really interesting here.

Exactly. Unrelieved chronic pain, the kind gabapentin targets, isn't just uncomfortable; it seems to accelerate biological aging. A study in GeroScience 2025, for example, found painful diabetic neuropathy was linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy.

So, effectively addressing chronic pain, where appropriate, might actually have a beneficial impact on our biological age and overall health span. However, the drugs themselves come with risks, especially concerning long-term safety and mortality.

Absolutely. While gabapentin can be life-changing for some with neuropathic pain, especially if it’s severe and resistant to other treatments, we need to consider the full picture.

The challenge is that robust long-term data on gabapentin's direct impact on all-cause mortality, independent of the underlying pain condition, is still evolving. We know about common side effects, but linking the medication itself to overall survival is complex.

Precisely. We can't say the channel itself "causes death." The aging story is really about chronic pain's systemic effects and the careful balance of benefits versus risks with the drugs that intervene here. For some, the relief enables better quality of life and potentially mitigates pain's aging effects; for others, the risks might outweigh the benefits. What's still unknown is whether gabapentin, for a given individual, truly alters their long-term mortality risk.